HER2-targeted therapies for the treatment of HER2-positive advanced breast cancer involve monoclonal antibodies such as trastuzumab and pertuzumab; ADCs such as trastuzumab emtansine (T-DM1) and T-DXd; and the small-molecule tyrosine kinase inhibitors for HER2 (Gradishar et al., 2022; Gennari et al., 2021). Here, ERBB2 is linked to breast carcinoma.